Exciting news for anyone dealing with high cholesterol! A new jab, Leqvio (also known as inclisiran), could be a game changer for heart care. This twice-a-year injection has shown incredible promise in helping patients hit their cholesterol targets faster and with fewer side effects than traditional treatments like statins.
Recent trial data revealed that a whopping 85% of patients receiving Leqvio met their cholesterol goals within 90 days, compared to just 31% on a placebo. Plus, those on Leqvio reported 43% less muscle pain—often a complaint about statins.
Why is this important? High cholesterol, particularly the “bad” kind, can clog your arteries and increase risk of heart attacks and strokes. Statins have been the go-to treatment, but they require daily doses. Now, Leqvio offers a simpler solution: an initial injection, another at three months, and then just twice a year thereafter.
Experts believe this might revolutionise cholesterol management and cardiovascular care, giving patients a more effective and convenient option. This comes as the latest NHS survey indicates over 53% of adults in England have raised cholesterol levels—a number that’s climbed in recent years.
With the findings soon to be shared at the European Society of Cardiology Congress, many are hopeful that Leqvio can become a cornerstone in modern heart disease treatment. Keep an eye out for more updates as further details emerge on this promising development!